British Airways Pensions Investment Management Ltd lifted its position in Bristol-Myers Squibb Co (NYSE:BMY) by 82.3% in the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 476,760 shares of the biopharmaceutical company’s stock after acquiring an additional 215,246 shares during the quarter. British Airways Pensions Investment Management Ltd’s holdings in Bristol-Myers Squibb were worth $30,381,000 as of its most recent SEC filing.
Several other hedge funds have also recently added to or reduced their stakes in BMY. Tradewinds Capital Management LLC raised its holdings in Bristol-Myers Squibb by 34.6% in the second quarter. Tradewinds Capital Management LLC now owns 1,945 shares of the biopharmaceutical company’s stock worth $108,000 after purchasing an additional 500 shares in the last quarter. Atlantic Trust LLC bought a new position in Bristol-Myers Squibb in the second quarter worth about $111,000. Massey Quick Simon & CO. LLC raised its holdings in Bristol-Myers Squibb by 523.5% in the third quarter. Massey Quick Simon & CO. LLC now owns 1,777 shares of the biopharmaceutical company’s stock worth $113,000 after purchasing an additional 1,492 shares in the last quarter. Blue Chip Partners Inc. raised its holdings in Bristol-Myers Squibb by 0.7% in the second quarter. Blue Chip Partners Inc. now owns 2,156 shares of the biopharmaceutical company’s stock worth $120,000 after purchasing an additional 15 shares in the last quarter. Finally, BDO Wealth Advisors LLC bought a new position in Bristol-Myers Squibb in the second quarter worth about $123,000. Hedge funds and other institutional investors own 69.74% of the company’s stock.
BMY has been the subject of a number of recent research reports. SunTrust Banks upgraded shares of Bristol-Myers Squibb from a “hold” rating to a “buy” rating in a report on Monday, October 30th. Zacks Investment Research upgraded shares of Bristol-Myers Squibb from a “hold” rating to a “buy” rating and set a $68.00 target price for the company in a report on Wednesday, November 1st. Barclays boosted their target price on shares of Bristol-Myers Squibb from $58.00 to $65.00 and gave the stock an “equal weight” rating in a report on Friday, October 13th. Vetr downgraded shares of Bristol-Myers Squibb from a “hold” rating to a “sell” rating and set a $59.70 target price for the company. in a report on Thursday, December 28th. Finally, BMO Capital Markets set a $49.00 target price on shares of Bristol-Myers Squibb and gave the stock a “sell” rating in a report on Thursday, October 26th. Three analysts have rated the stock with a sell rating, eight have issued a hold rating and ten have issued a buy rating to the stock. The stock currently has a consensus rating of “Hold” and an average price target of $65.11.
In related news, EVP Sandra Leung sold 156,582 shares of the company’s stock in a transaction that occurred on Monday, December 4th. The stock was sold at an average price of $63.37, for a total value of $9,922,601.34. Following the sale, the executive vice president now owns 584,373 shares in the company, valued at $37,031,717.01. The sale was disclosed in a legal filing with the SEC, which is available through this link. Also, EVP Thomas J. Jr. Lynch sold 5,300 shares of the company’s stock in a transaction that occurred on Tuesday, December 12th. The shares were sold at an average price of $63.24, for a total value of $335,172.00. Following the completion of the sale, the executive vice president now owns 9,251 shares in the company, valued at approximately $585,033.24. The disclosure for this sale can be found here. Corporate insiders own 0.23% of the company’s stock.
Bristol-Myers Squibb Co (NYSE:BMY) opened at $61.85 on Thursday. Bristol-Myers Squibb Co has a fifty-two week low of $46.01 and a fifty-two week high of $66.10. The company has a current ratio of 1.59, a quick ratio of 1.46 and a debt-to-equity ratio of 0.47. The stock has a market cap of $101,230.00, a PE ratio of 24.35, a PEG ratio of 2.30 and a beta of 1.18.
Bristol-Myers Squibb (NYSE:BMY) last posted its quarterly earnings data on Thursday, October 26th. The biopharmaceutical company reported $0.75 earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of $0.77 by ($0.02). Bristol-Myers Squibb had a net margin of 20.56% and a return on equity of 32.41%. The company had revenue of $5.25 billion for the quarter, compared to analyst estimates of $5.20 billion. During the same quarter last year, the company earned $0.77 EPS. The business’s revenue was up 6.7% compared to the same quarter last year. sell-side analysts forecast that Bristol-Myers Squibb Co will post 2.99 EPS for the current year.
The business also recently disclosed a quarterly dividend, which will be paid on Thursday, February 1st. Stockholders of record on Friday, January 5th will be issued a dividend of $0.40 per share. The ex-dividend date of this dividend is Thursday, January 4th. This represents a $1.60 annualized dividend and a dividend yield of 2.59%. This is an increase from Bristol-Myers Squibb’s previous quarterly dividend of $0.39. Bristol-Myers Squibb’s dividend payout ratio is 62.99%.
COPYRIGHT VIOLATION WARNING: This piece of content was first posted by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are viewing this piece of content on another website, it was copied illegally and reposted in violation of U.S. and international trademark & copyright law. The correct version of this piece of content can be viewed at https://www.dispatchtribunal.com/2018/01/18/british-airways-pensions-investment-management-ltd-purchases-215246-shares-of-bristol-myers-squibb-co-bmy.html.
Bristol-Myers Squibb Company Profile
Bristol-Myers Squibb Company is engaged in the discovery, development, licensing, manufacturing, marketing, distribution and sale of biopharmaceutical products. The Company’s pharmaceutical products include chemically synthesized drugs, or small molecules, and products produced from biological processes called biologics.
Want to see what other hedge funds are holding BMY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Bristol-Myers Squibb Co (NYSE:BMY).
Receive News & Ratings for Bristol-Myers Squibb Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bristol-Myers Squibb and related companies with MarketBeat.com's FREE daily email newsletter.